SomaGenics, an RNA-focused biotechnology company, expands its IP protection with three newly issued patents by the United States Patent and Trademark Office covering two of the Company's core RNA...
Read More »SomaGenics Awarded NIH Funding to Develop NGS Single-Cell Analysis of Small RNAs
SomaGenics announced the receipt of a Phase I SBIR grant from the NIH to develop RealSeq®-SC (Single Cell), expected to be the first commercially available library preparation kit for profiling small RNAs (including microRNAs) from single cells using NGS methods. ...
Read More »SomaGenics Granted New Patents for RNA Detection and RNA-based Therapeutics Technologies
SomaGenics, an RNA-focused biotechnology company, announced expansion of its intellectual property portfolio with issue of two new patents for its RNA analysis technologies (miR-ID® and RealSeq®) and European patent protection for its therapeutic short synthetic hairpin RNA (sshRNA) agents. MiR-ID®, ...
Read More »SomaGenics secures $1.8M in funding from NIH to further develop the Real-Seq® technology platform for small RNA sequencing
SomaGenics has been awarded a $1.8M two-year NIH SBIR Phase II grant to further develop its RealSeq®–AC technology for next-generation sequencing (NGS) of small RNAs such as microRNA. Real-Seq®-AC dramatically reduces bias in small RNA sequencing libraries compared to commercially ...
Read More »Somagenics Awarded Second NIH Grant to Develop resQ-RNA™ Technology to Quantify Fragmented mRNA From Degraded Samples
SANTA CRUZ, Calif. /PRNewswire/ — Somagenics has been awarded a second phase I SBIR grant from NIH to develop its resQ-RNATM technology for quantitative real-time PCR of fragmented RNA samples. Fragmentation of RNA is a particular problem in tissue samples that ...
Read More »